Nuclear Medicine Market to Reach USD 57.3 Bn by 2035, Expanding at a CAGR of 10.8% | Transparency Market Research

Advancing hybrid imaging systems, rising demand for early diagnosis, and growing prevalence of chronic diseases are driving global market expansion.

WILMINGTON, DE, UNITED STATES, September 19, 2025 /EINPresswire.com/ -- The global nuclear medicine market is poised for significant growth over the coming decade. Valued at US$ 18.6 billion in 2024, the industry is projected to expand at a CAGR of 10.8% between 2025 and 2035, surpassing US$ 57.3 billion by the end of 2035. Increasing adoption of PET and SPECT imaging technologies, rising geriatric populations, and growing demand for early detection of cancer, cardiovascular, and neurological conditions are fueling market expansion.

With advancements in radiopharmaceuticals and imaging equipment, nuclear medicine enables physicians to detect disease at earlier stages and tailor patient treatment more effectively. In addition to diagnostics, targeted radionuclide therapies are emerging as promising treatment options for oncology and other conditions, supporting long-term market growth.

Full Market Report available for delivery. For purchase or customization, please request here –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4672

Market Overview

The nuclear medicine market encompasses a wide range of diagnostic and therapeutic products. Diagnostic applications, particularly PET and SPECT imaging, dominate due to their ability to capture functional and metabolic information beyond traditional imaging methods. These technologies provide superior accuracy in disease detection, enabling physicians to make informed treatment decisions and improve patient outcomes.

Therapeutic applications, including radionuclide-based therapies and brachytherapy, are rapidly expanding as new cancer treatments gain regulatory approval. Radiopharmaceuticals such as Iodine-131, Yttrium-90, and Lutetium-177 are increasingly being adopted in oncology for targeted therapy.

Market growth, however, faces challenges such as isotope shortages, high procedural costs, and regulatory complexities. Addressing these barriers will be critical for ensuring accessibility and broad adoption across healthcare systems.

Analyst Viewpoint

Analysts at Transparency Market Research highlight that the nuclear medicine industry is witnessing unprecedented growth, driven by hybrid imaging systems and advances in radiopharmaceutical development. PET/CT and SPECT/CT systems provide precise anatomical and functional data in a single scan, enhancing diagnostic accuracy and treatment planning.

The increasing emphasis on early diagnosis and preventive healthcare is bolstering demand for nuclear medicine products. Hospitals and diagnostic centers are investing heavily in advanced imaging technologies, while the aging population worldwide is generating steady demand for nuclear medicine procedures.

However, affordability challenges and isotope supply chain constraints remain pressing concerns. Companies that invest in production scalability, affordable solutions, and strategic partnerships will be best positioned to capture market share.

Key Drivers of Market Growth

1. Growing Adoption of Hybrid Imaging Systems

Hybrid PET/CT and SPECT/CT technologies integrate anatomical and functional imaging, offering improved accuracy for cancer, cardiovascular, and neurological diagnoses. These systems optimize workflow, reduce patient radiation exposure, and support precise treatment planning, making them highly desirable in modern healthcare.

2. Increased Demand for Early and Accurate Diagnosis

The rising burden of cancer, cardiovascular diseases, and neurological disorders underscores the importance of early diagnosis. Nuclear medicine enables physicians to detect metabolic abnormalities before anatomical changes occur, enhancing treatment efficacy and improving patient outcomes.

3. Expanding Role of Radiopharmaceuticals in Therapeutics

Targeted radionuclide therapies are gaining ground in oncology, with novel agents like Lutetium-177 and Actinium-based therapies demonstrating strong efficacy. These treatments minimize collateral damage to healthy tissue, supporting the global shift toward precision medicine.

Segment Analysis

By Product Type

Diagnostic Products: PET tracers (F-18, Rb-82, N-13, C-11), SPECT tracers (TC-99m, Tl-201, Ga-67, I-123), and others.

Therapeutic Products: Alpha emitters (Ra-223, Bi-213), Beta emitters (I-131, Y-90, Lu-177, Sm-153), and Brachytherapy isotopes (Cs-131, I-125, Pd-103, Ir-192).

By Application

Cardiology, Neurology, Oncology, Thyroid disorders, Lymphoma, Bone metastasis, Endocrine tumors, and others.

By End-User

Hospitals & clinics, diagnostic centers, and research laboratories.

Regional Insights

North America leads the global market, supported by advanced healthcare infrastructure, strong R&D investments, and widespread adoption of hybrid imaging systems. Favorable reimbursement policies further support demand.

Europe is expanding steadily, with high adoption in Germany, the U.K., and France driven by precision medicine initiatives and government support for cancer research.

Asia Pacific is expected to witness the fastest growth, led by rising healthcare investments in China, India, and Japan. Growing awareness and increasing availability of radiopharmaceuticals are driving regional adoption.

Latin America and Middle East & Africa show steady growth potential but remain constrained by limited infrastructure and affordability challenges.

Key Players and Industry Leaders

Prominent companies in the global nuclear medicine market include:

Cardinal Health

Jubilant Pharma Company

The Bracco Group

Nordion (Canada) Inc.

NTP Radioisotopes SOC Ltd.

ECZACIBAŞI-MONROL

Lantheus

China Isotope & Radiation Corporation

Eckert & Ziegler Medical

Mallinckrodt plc

GE HealthCare

Blue Earth Diagnostics

NorthStar Medical Radioisotopes, LLC

B. J. Madan & Co

Curium Pharma

Novartis AG

Bayer AG

These players are focusing on radiopharmaceutical innovation, isotope production, and expanding diagnostic and therapeutic portfolios through strategic partnerships, mergers, and regulatory approvals.

Recent Developments

June 2025 – GE HealthCare received U.S. FDA approval for its Vizamyl PET imaging agent for beta-amyloid detection, expanding indications and enhancing diagnostic precision in Alzheimer’s disease.

March 2025 – Actinium Pharmaceuticals announced ATNM-400, a novel non-PSMA-targeting radiotherapy for prostate cancer, offering new treatment avenues beyond existing options.

Opportunities and Challenges

Opportunities:

Rising adoption of hybrid imaging technologies

Expansion of therapeutic radiopharmaceutical applications

Growth in personalized and precision medicine

Increasing healthcare investments in emerging economies

Challenges:

High costs of nuclear medicine procedures

Regulatory complexities and isotope shortages

Limited awareness and infrastructure in developing regions

Market Trends

Integration of PET/CT and SPECT/CT hybrid systems

Expansion of targeted radionuclide therapies in oncology

Increased investment in isotope production facilities

Adoption of AI-enabled imaging for improved diagnostics

Future Outlook

The nuclear medicine market is expected to maintain strong double-digit growth through 2035. With expanding applications in both diagnostics and therapeutics, coupled with advances in radiopharmaceutical development and hybrid imaging technologies, the sector is positioned to play a central role in precision medicine. Companies that focus on innovation, affordability, and reliable isotope supply will capture significant growth opportunities worldwide.

Why Buy This Report?

Market size forecasts and CAGR projections through 2035

Comprehensive segment analysis (product type, application, end-user, region)

Competitive landscape with detailed profiles of leading players

Insights into emerging trends, opportunities, and challenges

Coverage of technological advancements and regulatory developments

Explore Latest Research Reports by Transparency Market Research:

Self-sampling Blood Collection and Storage Devices Market - https://www.transparencymarketresearch.com/selfsampling-blood-collection-and-storage-device-market.html

Blood Testing Market - https://www.transparencymarketresearch.com/blood-testing-market.html

Clinical Laboratory Services Market - https://www.transparencymarketresearch.com/clinical-laboratory-services-market-report.html

Cord Blood Banking Services Market - https://www.transparencymarketresearch.com/cord-blood-banking-services.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants uses proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

Atil Chaudhari
Transparency Market Research Inc.
+1 518-618-1030
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.